Sunder Biomedical Tech Co (ROCO:4115) Research & Development: NT$30.0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4115 Sunder Biomedical Tech Co Ltd ROCO:4115
52 GF Score
Price NT$7.86
GF Value NT$10.70
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sunder Biomedical Tech Co Research & Development?

Sunder Biomedical Tech Co ROCO:4115 +0.38% 52 Research & Development is NT$30.0 Mil as of Dec. 2025. GuruFocus rates ROCO:4115 with a GF Score™ of 52/100 and a GF Value™ of NT$10.70 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Sunder Biomedical Tech Co's Research & Development for the six months ended in Dec. 2025 was NT$15.5 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$30.0 Mil.

Sunder Biomedical Tech Co  (ROCO:4115) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Sunder Biomedical Tech Co Research & Development Related Terms

Sunder Biomedical Tech Co Research & Development Historical Data

* Premium members only.

The historical data trend for Sunder Biomedical Tech Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sunder Biomedical Tech Co Research & Development Chart

Sunder Biomedical Tech Co Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial 25.63 29.32 29.44 28.03 30.00

Sunder Biomedical Tech Co Semi-Annual Data
Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 15.29 14.02 14.01 14.46 15.55
ROCO:4115
52GF Score
Sunder Biomedical Tech Co Ltd ROCO:4115
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sunder Biomedical Tech Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$30.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$30.0 Mil mean?
Sunder Biomedical Tech Co (ROCO:4115) has a Research & Development of NT$30.0 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Sunder Biomedical Tech Co and its competitors.
Is Sunder Biomedical Tech Co's Research & Development too high?
Sunder Biomedical Tech Co's current Research & Development is NT$30.0 Mil. Overall, Sunder Biomedical Tech Co has a GF Score™ of 52/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sunder Biomedical Tech Co's Research & Development compare to ISRG and BDX?
Sunder Biomedical Tech Co's Research & Development of NT$30.0 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Devices & Instruments company?
A good Research & Development depends on the Medical Devices & Instruments industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Sunder Biomedical Tech Co and its competitors. Sunder Biomedical Tech Co's current Research & Development is NT$30.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunder Biomedical Tech Co stock overvalued right now?
Based on GuruFocus' analysis, Sunder Biomedical Tech Co (ROCO:4115) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$10.70, compared to a current price of NT$7.86 — trading 26.5% below its estimated fair value. The current Research & Development is NT$30.0 Mil. Sunder Biomedical Tech Co's overall GF Score™ is 52/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Sunder Biomedical Tech Co (ROCO:4115), the current Research & Development is NT$30.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sunder Biomedical Tech Co (ROCO:4115) Overvalued in 2026?

Based on GuruFocus' analysis, Sunder Biomedical Tech Co stock appears to be undervalued. The current stock price of NT$7.86 is trading 26.5% below its estimated GF Value™ of NT$10.70. GuruFocus considers Sunder Biomedical Tech Co to be Modestly Undervalued.

Key valuation signals for ROCO:4115:

  • Research & Development: NT$30.0 Mil
  • GF Value™: NT$10.70 vs. price of NT$7.86 (26.5% below fair value)
  • GF Score™: 52/100 with 4 warning signs

No single metric tells the full story. See the ROCO:4115 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sunder Biomedical Tech Co Business Description

Address No. 1-67, Zhongzheng Road, Chung-Ming Village, Pao-Chung Hsiang, Yunlin, TWN, 63441
Sunder Biomedical Tech Co Ltd is engaged in providing medical devices. Its products include Protective Goggles; Meltblown Nonwoven Fabric/Mask; Suction Irrigation Set; Smoke Filter; Endo Bag; Blood Line Set for Hemodialysis and others.
52GF Score

Get the complete analysis for ROCO:4115

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$7.86
Price
NT$10.70
GF Value